Retina

Aflibercept 8 mg offers superior benefits for nAMD over aflibercept 2 mg

The Phase 3 PULSAR trial demonstrated that aflibercept 8 mg provides greater therapeutic benefits and an extended injection interval, with equivalent safety, compared to aflibercept 2 mg in the treatment of neovascular age-related macular degeneration (nAMD), according to data presented at ASRS 2023. The ongoing trial aims to evaluate the...